Posted on 07/04/2009 in Pharmaceutical Company Product News Hospira has received marketing authorisation for injectible piperacillin/tazobactam in the UK to treat patients with moderate to severe infections.
The drug is a generic version of Wyeth's tazocin, which is one of the world's leading needle-administered antibiotic.
Hospira's latest product will play a significant role in reducing the price of the treatment across the European Union (EU), according to the company's Europe, Middle East and Africa president Michael Kotsanis.
"This furthers our goal of taking costs out of the healthcare system by providing high-quality, lower-cost alternatives to proprietary medications," he commented.
Piperacillin/tazobactam is expected to be launched in other markets across the continent in coming months and it will be available as a powder for solution in injections or infusion in 2.25 g and 4.5 g single-dose vials.
Last month, Hopsira signed an agreement with Hikma to market a number of generic injectible pharmaceutical products.
Under the terms of the deal, the former receives the rights to distribute several items from the latter's portfolio in the UK, France and Spain. Other news stories from 07/04/2009
Read more in the Zenopa News Archive
How this news is generated
|
